Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 2/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.32 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | PRKDC | P78527 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30765656 | 0.94 | KMT2A (0.34) | USP2POLBGAAMAPK1HTT | |
| SCHEMBL30765754 | 0.84 | MAPK1 (0.34) | MAPK1 | |
| SCHEMBL30765748 | 0.78 | SOS1 (0.40) | GAAMAPK1HTTLMNANPSR1 | |
| SCHEMBL30766072 | 0.74 | SOS1 (0.39) | GAAALDH1A1PRKDC | |
| SCHEMBL30765863 | 0.72 | GAA (0.38) | USP2POLBGAAMAPK1HTT | |
| SCHEMBL30765645 | 0.72 | MAPK1 (0.35) | USP2MAPK1ALDH1A1 | |
| SCHEMBL30765672 | 0.71 | ALDH1A1 (0.33) | POLBGAAHTTLMNANPSR1 | |
| SCHEMBL30766079 | 0.69 | TSHR (0.38) | GAALMNAALDH1A1 | |
| SCHEMBL30766002 | 0.68 | USP2 (0.37) | USP2POLBGAAMAPK1HTT | |
| SCHEMBL31558425 | 0.67 | MEN1 (0.36) | LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4568666-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | Alexion Pharmaceuticals, Inc. (US) | 2025-06-18 | — | — | EP | disclosed |
| WO-2024035686-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ALEXION PHARMACEUTICALS, INC. (US) | 2024-02-15 | — | — | WO | disclosed |